X-Linked Hypophosphatemic Rickets Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2023 Update
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
X-Linked Hypophosphatemic Rickets Clinical Trials Overview
The X-Linked Hypophosphatemic Rickets clinical trial report consists of 55 trials. The report provides an overview of the X-Linked Hypophosphatemic Rickets clinical trial scenario. The report provides top-line data relating to the clinical trials on X-Linked Hypophosphatemic Rickets. It also includes an overview of trial numbers and their average enrolment in top countries conducted across the globe. Moreover, it offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status, and sponsor type. The report includes the names of prominent sponsors involved with conducting the X-Linked Hypophosphatemic Rickets clinical trials as well.
Key Regions | · Asia-Pacific
· Europe · North America · Middle East and Africa · South and Central America |
Key Countries | · The US
· Japan · China · Canada · France · South Korea |
Key Sponsor Types | · Company
· Institution |
Leading Sponsors | · Kirin Holdings Co Ltd
· Ultragenyx Pharmaceutical Inc · ICON Plc · Kelun Industrial Group Company Limited · LEO Foundation |
Enquire & Decide | Discover the perfect solution for your business needs. Enquire now and let us help you make an informed decision before making a purchase. |
X-Linked Hypophosphatemic Rickets Clinical Trials Segmentation by Regions and Countries
Asia-Pacific led the X-Linked Hypophosphatemic Rickets clinical trials landscape with more than 35% of the clinical trials conducted there as of October 2023.
The key regions considered for X-Linked Hypophosphatemic Rickets clinical trials analysis are Asia-Pacific, Europe, North America, the Middle East and Africa, and South and Central America.
In a country-wise analysis, as of October 2023, the US accounted for the highest number of X-Linked Hypophosphatemic Rickets clinical trials, followed by Japan and China.
G7 countries: Among the G7 (United States, United Kingdom, Germany, Canada, Japan, France, and Italy) countries, France has the highest proportion of X-Linked Hypophosphatemic Rickets to Nutritional Disorders clinical trials as of October 2023.
E7 countries: Among the E7 (China, India, Russia, Turkey, Brazil, Mexico, and Indonesia) countries, China has the highest proportion of X-Linked Hypophosphatemic Rickets to Nutritional Disorders clinical trials as of October 2023.
X-Linked Hypophosphatemic Rickets Clinical Trials Analysis by Regions, 2023 (%)
Buy the Full Report for More Regional Insights into the X-Linked Hypophosphatemic Rickets Clinical Trials
X-Linked Hypophosphatemic Rickets Clinical Trials Segmentation by Sponsor Types
The key sponsor types for X-Linked Hypophosphatemic Rickets clinical trials are company and institution. As of October 2023, the company sponsor type dominated the X-Linked Hypophosphatemic Rickets clinical trials share.
X-Linked Hypophosphatemic Rickets Clinical Trials Analysis by Sponsor Types, 2023 (%)
Buy Full Report for More Sponsor Type Insights into X-Linked Hypophosphatemic Rickets Clinical Trials
X-Linked Hypophosphatemic Rickets Clinical Trials - Competitive Landscape
In 2023, Kirin Holdings Co Ltd conducted the highest number of X-Linked Hypophosphatemic Rickets clinical trials.
Some of the leading companies for X-Linked Hypophosphatemic Rickets clinical trials are:
- Kirin Holdings Co Ltd
- Ultragenyx Pharmaceutical Inc
- ICON Plc
- Kelun Industrial Group Company Limited
- LEO Foundation
X-Linked Hypophosphatemic Rickets Clinical Trials Analysis by Leading Companies, 2023 (%)
Buy Full Report to Know More about the Leading Players of X-Linked Hypophosphatemic Rickets Clinical Trials
Segments Covered in the Report
X-Linked Hypophosphatemic Rickets Clinical Trials Regional Outlook (2023)
- Asia-Pacific
- Europe
- North America
- Middle East and Africa
- South and Central America
X-Linked Hypophosphatemic Rickets Clinical Trials Country Outlook (2023)
- The US
- Japan
- China
- Canada
- France
- South Korea
X-Linked Hypophosphatemic Rickets Clinical Trials Sponsor Type Outlook (2023)
- Company
- Institution
Scope
- The report provides a snapshot of the global clinical trials landscape.
- The report provides top-level data related to the clinical trials by region, country (G7 & E7), trial status, trial phase, sponsor type, and endpoint status.
- The report reviews the top companies involved and enlists all trials (trial title, phase, and status) pertaining to the company.
- The report provides all the unaccomplished trials (terminated, suspended, and withdrawn) with a reason for accomplishment.
- The report provides enrollment trends for the past five years.
- The report provides the latest news for the past three months.
Reasons to Buy
- Assists in formulating key business strategies with regard to investment.
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost.
- Provides top-level analysis of the global clinical trials market which helps identify key business opportunities.
- Supports understanding of trial count and enrollment trends by country in the global therapeutics market.
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted trials.
- Facilitates clinical trial assessment of the indication on a global, regional, and country level.
Ultragenyx Pharmaceutical Inc
ICON Plc
Kelun Industrial Group Company Limited
LEO Foundation
Sichuan Kelun Industrial Group Co Ltd
Changchun High-Tech Industry Group Co Ltd
Hainan Huluwa Pharmaceutical Group Co Ltd
Jiangsu Kanion Pharmaceutical Co Ltd
Lunan Pharmaceutical Group Co Ltd
Table of Contents
Table
Figures
Frequently asked questions
-
Which region accounted for the highest number of X-Linked Hypophosphatemic Rickets clinical trials?
Asia-Pacific accounted for the highest number of X-Linked Hypophosphatemic Rickets clinical trials as of October 2023.
-
Which country conducted the highest number of X-Linked Hypophosphatemic Rickets clinical trials?
The US conducted the highest number of X-Linked Hypophosphatemic Rickets clinical trials as of October 2023.
-
Which sponsor type was the most prominent in the X-Linked Hypophosphatemic Rickets clinical trials?
The company was the most prominent sponsor type for X-Linked Hypophosphatemic Rickets clinical trials.
-
Who are the leading companies of X-Linked Hypophosphatemic Rickets clinical trials?
Some of the leading companies of X-Linked Hypophosphatemic Rickets clinical trials are Kirin Holdings Co Ltd, Ultragenyx Pharmaceutical Inc, ICON Plc, Kelun Industrial Group Company Limited, and LEO Foundation, among others.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.